Hyperliquid Strategies aims to raise up to $1 billion by issuing 160 million shares

Hyperliquid Strategies aims to raise up to $1 billion by issuing 160 million shares

Hyperliquid Strategies has filed a registration statement (S-1) with the SEC. Through a public offering, it seeks to raise up to $1 billion and will issue up to 160 million shares.

The company is the Sonnet BioTherapeutics–Rorschach I merger entity and is expected to list on Nasdaq under a new ticker.